Farmas USA

ANTH 0,71 x 0,72. BREAKOUT!!

una a tener en cuenta
http://seekingalpha.com/article/1032471-is-neuralstem-the-next-sarepta

A CLSN, por mucho que corra, la estaré esperando, y entonces ZASSSSSS,y al gallinero. Y que ponga todos los huevos que tenga que poner.

Cuidado con CUR, leeros de este artículo , lo que cuentan de ella.
Es la última de las farmas analizadas.
http://seekingalpha.com/article/1043471-maxim-group-highlights-3-stem-cell-stocks-to-consider-and-1-to-avoid?source=yahoo

a cuanto la esperas???? importante...

alguna noticia sobre GERN, hoy pega un buen capuzon de -25%..., y es de las que me gustan , pero otra que me engancha....

Otra que le zurran es PPHM con la rachita buena que llevaba...

Puede ser por el artículo malo de su CEO http://www.thestreet.com/story/11782309/1/your-vote-counts-who-is-the-worst-biotech-ceo-of-2012.html

o por el anuncio de presentación de resultados http://www.equities.com/news/headline-story?dt=2012-12-03&val=783084&cat=hcare

Me preocupa mas esto último... Como lo veis??

GERN. La bajada se debe a que van a recortar su plantilla en un 40%, van a sustituir a su director financiero y han interrumpido el desarrollo de GRN1005, su tratamiento para el cáncer cerebral.

Geron shares (US:GERN) fell 12% to $1.38 after a brief trading halt.The Menlo Park, Calif.-based company said its restructuring will include cutting its workforce by 40%, to 64 full-time positions, and that it will replace Chief Financial Officer Graham Cooper.

Geron’s decision to discontinue development of brain-cancer treatment GRN1005 was made after the company completed a planned interim analysis for GRABM-B, a Phase 2 study in patients with brain metastases arising from breast cancer. The analysis showed there were no confirmed intra-cranial responses among the first 30 evaluable patients in the trial. See: Geron to discontinue brain-cancer drug development.

The company will also discontinue GRABM-L, a Phase 2 study in patients with brain metastases arising from non-small cell lung cancer, “because of the inability to successfully enroll the trial,” it said in a statement.

Geron expects the restructuring to cut annual cash operating expenses to about $33 million in 2013, from about $65 million in 2012.